SAN DIEGO — Sydnexis Inc., a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the risk of comorbidities, has appointed Nick Ruth, MBA, as Chief Commercial Officer. With 25 years of experience in both the ophthalmic pharmaceutical and surgical industries, he will lead the company’s commercial strategy and transition from a clinical organization to both a clinical and commercial company.
Prior to joining Sydnexis, he held prominent roles at several leading companies, including Carl Zeiss Meditec, Alcon, and Novartis. He brings a wealth of knowledge in leading product launches and building successful brands and teams.
“We are thrilled to welcome Nick to Sydnexis as our new Chief Commercial Officer,” said Patrick Johnson, President of Sydnexis. “With his background in creating and building teams and spearheading numerous product launches, we are looking forward to Nick playing a vital role in the continued growth of our company.”
“It is a privilege and I am honored to join Sydnexis to further our mission to treat progressive myopia in children and minimize the risk of associated sight-threatening conditions later in life,” said Nick Ruth. “Success in achieving this mission does not happen organically. It is the result of having a great team of people who are passionate and selfless in achieving this mission. I am looking forward to collaborating with the talented team at Sydnexis to help fight this significant and growing unmet need.”
Founded in 2014, Sydnexis is a privately held, clinical stage biopharmaceutical company currently conducting its pivotal Phase 3 clinical trial, evaluating its proprietary low-dose atropine formulation for the treatment of progressive myopia in pediatric patients. Phase 3 data will be available in the second quarter of 2024.
